Mostrar el registro sencillo del ítem
| dc.contributor.author | Ding, Wern-Yew | |
| dc.contributor.author | Rivera-Caravaca, José-Miguel | |
| dc.contributor.author | Marín, Francisco | |
| dc.contributor.author | Torp-Pedersen, Christian | |
| dc.contributor.author | Roldán-Schilling, Vanessa | |
| dc.contributor.author | Lip, Gregory-YH | |
| dc.date.accessioned | 2025-11-18T12:47:28Z | |
| dc.date.available | 2025-11-18T12:47:28Z | |
| dc.date.issued | 2021-08 | |
| dc.identifier.citation | Ding WY, Rivera-Caravaca JM, Marin F, Torp-Pedersen C, Roldán V, Lip GYH. Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS. JCM. 29 de julio de 2021;10(15):3357. | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/20915 | |
| dc.description.abstract | Our ability to evaluate residual stroke risk despite anticoagulation in atrial fibrillation (AF) is currently lacking. The Calculator of Absolute Stroke Risk (CARS) has been proposed to predict 1-year absolute stroke risk in non-anticoagulated patients. We aimed to determine whether a modified CARS (mCARS) may be used to assess the residual stroke risk in anticoagulated AF patients from 'real-world' and 'clinical trial' cohorts. We studied patient-level data of anticoagulated AF patients from the real-world Murcia AF Project and AMADEUS clinical trial. Individual mCARS were estimated for each patient. None of the patients were treated with non-vitamin K antagonist oral anticoagulants. The predicted residual stroke risk was compared to actual stroke risk. 3503 patients were included (2205 [62.9%] clinical trial and 1298 [37.1%] real-world). There was wide variation of CARS for each category of CHA(2)DS(2)-VASc score in both cohorts. Average predicted residual stroke risk by mCARS (1.8 ± 1.8%) was identical to actual stroke risk (1.8% [95% CI, 1.3-2.4]) in the clinical trial, and broadly similar in the real-world (2.1 ± 1.9% vs. 2.4% [95% CI, 1.6-3.4]). AUCs of mCARS for prediction of stroke events in the clinical trial and real-world were 0.678 (95% CI, 0.598-0.758) and 0.712 [95% CI, 0.618-0.805], respectively. mCARS was able to refine stroke risk estimation for each point of the CHA(2)DS(2)-VASc score in both cohorts. Personalised residual 1-year absolute stroke risk in anticoagulated AF patients may be estimated using mCARS, thereby allowing an assessment of the absolute risk reduction of treatment and facilitating a patient-centred approach in the management of AF. Such identification of patients with high residual stroke risk could help target more aggressive interventions and follow-up. | |
| dc.language.iso | eng | |
| dc.publisher | MDPI | |
| dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
| dc.title | Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 34362143 | |
| dc.relation.publisherversion | https://www.mdpi.com/2077-0383/10/15/3357 | |
| dc.identifier.doi | 10.3390/jcm10153357 | |
| dc.journal.title | Journal of Clinical Medicine | |
| dc.identifier.essn | 2077-0383 |